Tags

Type your tag names separated by a space and hit enter

[Left ventricular hypertrophy in chronic kidney disease].
G Ital Nefrol. 2006 Nov-Dec; 23(6):560-8.GI

Abstract

Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk. Left ventricular (LV) hypertrophy (LVH), together with coronary artery disease, has been considered the main target of intervention. LVH is highly prevalent in CKD even in early stages, as compared to general non-selected population. This is mainly due to the multifactorial pathogenesis of LVH in renal patients where both haemodynamic and non-haemodynamic stimuli synergically act inducing either an increase in left ventricular mass or an LV dilation. Anaemia and arterial hypertension seem to be the most important factors. Interventional studies have shown that partial correction of anaemia through epoetin, together with an arterial hypertension successful therapy through renin-angiotensin system acting drugs, such as ACE-inhibitors, were able to induce a LVH regression in CKD. Indeed, the unfavourable outcome in patients with both CKD and LVH, whose survival is reduced and incidence of fatal and non-fatal CV events increased, can be reversed if LVH is regressed by therapy. The most promising strategy in CKD seems to be LVH early diagnosis through echocardiography, the correct screening of risk factors, a LVM longitudinal monitoring through echo, as well as starting treatment in the early stages of CKD, with the aim of improving general and CV prognosis for these patients.

Authors+Show Affiliations

Divisione di Nephrologia, Dialisi e Trapianto, Azienda Ospedaliera Universitaria S. Martino, Genova. ernesto.paoletti@hsanmartino.itNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

ita

PubMed ID

17173262

Citation

Paoletti, E, and G Cannella. "[Left Ventricular Hypertrophy in Chronic Kidney Disease]." Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia, vol. 23, no. 6, 2006, pp. 560-8.
Paoletti E, Cannella G. [Left ventricular hypertrophy in chronic kidney disease]. G Ital Nefrol. 2006;23(6):560-8.
Paoletti, E., & Cannella, G. (2006). [Left ventricular hypertrophy in chronic kidney disease]. Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia, 23(6), 560-8.
Paoletti E, Cannella G. [Left Ventricular Hypertrophy in Chronic Kidney Disease]. G Ital Nefrol. 2006 Nov-Dec;23(6):560-8. PubMed PMID: 17173262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Left ventricular hypertrophy in chronic kidney disease]. AU - Paoletti,E, AU - Cannella,G, PY - 2006/12/19/pubmed PY - 2007/2/28/medline PY - 2006/12/19/entrez SP - 560 EP - 8 JF - Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia JO - G Ital Nefrol VL - 23 IS - 6 N2 - Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk. Left ventricular (LV) hypertrophy (LVH), together with coronary artery disease, has been considered the main target of intervention. LVH is highly prevalent in CKD even in early stages, as compared to general non-selected population. This is mainly due to the multifactorial pathogenesis of LVH in renal patients where both haemodynamic and non-haemodynamic stimuli synergically act inducing either an increase in left ventricular mass or an LV dilation. Anaemia and arterial hypertension seem to be the most important factors. Interventional studies have shown that partial correction of anaemia through epoetin, together with an arterial hypertension successful therapy through renin-angiotensin system acting drugs, such as ACE-inhibitors, were able to induce a LVH regression in CKD. Indeed, the unfavourable outcome in patients with both CKD and LVH, whose survival is reduced and incidence of fatal and non-fatal CV events increased, can be reversed if LVH is regressed by therapy. The most promising strategy in CKD seems to be LVH early diagnosis through echocardiography, the correct screening of risk factors, a LVM longitudinal monitoring through echo, as well as starting treatment in the early stages of CKD, with the aim of improving general and CV prognosis for these patients. SN - 0393-5590 UR - https://www.unboundmedicine.com/medline/citation/17173262/[Left_ventricular_hypertrophy_in_chronic_kidney_disease]_ L2 - http://www.diseaseinfosearch.org/result/3996 DB - PRIME DP - Unbound Medicine ER -